New drug SRN001 takes first step toward fighting lung scarring

NCT ID NCT07407543

Recruiting now Knowledge-focused Sponsor: siRNAgen Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial tests the safety and tolerability of an investigational drug called SRN001 in 30 healthy Korean and Caucasian men. Participants receive either SRN001 or a placebo to see how the drug moves through the body and whether it causes side effects. The goal is to gather early safety data that could support future studies in people with idiopathic pulmonary fibrosis, a serious lung-scarring disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SRN001
What this could lead to: If this early trial shows SRN001 is safe, it could pave the way for future studies testing it as a treatment for idiopathic pulmonary fibrosis.
What could go wrong: This is a very early Phase 1 trial in only 30 healthy volunteers, not patients with the disease. It is designed to check safety, not effectiveness, so there is no guarantee SRN001 will work for pulmonary fibrosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS

Contacts and locations

Locations

Seoul National University Hospital
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.